Consistent adherence to biologic therapies is critical for improving outcomes in asthma
Journal of Allergy and Clinical Immunology: Global · 2026-11 · 5 (6) · 100771
DOI: 10.1016/j.jacig.2026.100771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2026-11. Verfasst von Njira L Lugogo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
Evidence on real-world adherence to asthma biologic therapies and the relevance to clinical outcomes in asthma is limited.
Objective
We sought to evaluate biologic use patterns and the relationships between adherence, clinical, and health care resource utilization (HCRU) outcomes and economic burden in patients with asthma.
Methods
This was a retrospective observational study using Optum's de-identified Market Clarity Data (Optum Market Clarity) from 2007 to 2023 in adults in the United States with an asthma diagnosis in the 12 months before the first biologic dose (index date) who had ≥12 months of follow-up. Medication possession ratio (MPR; number of doses taken/dosing intervals) and group-based trajectory modeling (GBTM) identified distinct patient adherence patterns and assessed impact on exacerbations, HCRU, and costs (all-cause/asthma-related).
Results
Overall, 10,088 eligible patients were included in the MPR analysis; 54.7% discontinued treatment, 5.2% were minimally adherent, 20.3% were partially adherent, and 19.8% were adherent. Of these, 9,553 did not switch biologic during follow-up and were included in the GBTM analysis. For patients with 1 or more follow-up doses (n = 8,151), MPRs revealed suboptimal biologic adherence (average range, 40.6%-64.0%). GBTM identified 7 adherence clusters, with distinct adherence trajectories categorized from highest to lowest levels of biologic adherence. Patients with the highest adherence generally demonstrated the best outcomes. In patients in less adherent groups, increases were seen in exacerbations defined by asthma-related hospitalizations, all-cause HCRU, and all-cause health care costs. HCRU and asthma-related costs were generally lower for patients with the highest adherence.
Conclusions
Treatment adherence was consistently associated with better all-cause and asthma-related outcomes, highlighting the importance of biologic adherence in patients with asthma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
- Modena Health, La Jolla, Calif.
- Medical Affairs, GSK, Upper Providence, Pa.
- Cytel, Inc, Vancouver, British Columbia, Canada.
- Global Medical Affairs, Specialty Care, GSK, London, United Kingdom.
- Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia.
Förderung
- GSK
Zitieren
APA
Lugogo, N. L., Modena, B., Kwiatek, J., Wang, J., Howarth, P., Al-Lehebi, R., Vichiendilokkul, A., Karsanji, U., Hwee, J., Smith, G., Geason, R., Deb, A., & Alfonso-Cristancho, R. (2026). Consistent adherence to biologic therapies is critical for improving outcomes in asthma. Journal of Allergy and Clinical Immunology: Global, 5(6), 100771. https://doi.org/10.1016/j.jacig.2026.100771
Vancouver
Lugogo NL, Modena B, Kwiatek J, Wang J, Howarth P, Al-Lehebi R, et al. Consistent adherence to biologic therapies is critical for improving outcomes in asthma. Journal of Allergy and Clinical Immunology: Global. 2026;5(6):100771. doi:10.1016/j.jacig.2026.100771
BibTeX
@article{Lugogo2026,
author = {Lugogo, Njira L and Modena, Brian and Kwiatek, Justin and Wang, Jiaxuan and Howarth, Peter and Al-Lehebi, Riyad and Vichiendilokkul, Anna and Karsanji, Urvee and Hwee, Jeremiah and Smith, Gerald and Geason, Riley and Deb, Arijita and Alfonso-Cristancho, Rafael},
title = {Consistent adherence to biologic therapies is critical for improving outcomes in asthma},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2026},
volume = {5},
number = {6},
pages = {100771},
doi = {10.1016/j.jacig.2026.100771}
}
EUVIMED